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Abstract 
Background: The main genetic causes of homocystinuria are cystathionine beta-synthase (CBS) deficiency and the 
remethylation defects. Many patients present in childhood but milder forms may present later in life. Some countries 
have newborn screening programs for the homocystinurias but these do not detect all patients.
Results: HCU Network Australia is one of the very few support groups for patients with homocystinurias. Here we 
report the results of its survey of 143 patients and caregivers from 22 countries, evaluating current diagnostic path-
ways and management for the homocystinurias. Most (110) of the responses related to patients with CBS deficiency. 
The diagnosis was made by newborn screening in 20% of patients and in 50% of the others within 1 year of the initial 
symptom but in 12.5% it took over 15 years. The delay was attributed mainly to ignorance of the disease. Physicians 
need to learn to measure homocysteine concentrations in children with neurodevelopmental problems, and in 
patients with heterogeneous symptoms such as thromboembolism, dislocation of the optic lens, haemolytic uraemic 
syndrome, and psychiatric disease. Even when the diagnosis is made, the way it is communicated is sometimes poor. 
Early-onset CBS deficiency usually requires a low-protein diet with amino acid supplements. More than a third of the 
participants reported problems with the availability or cost of treatment. Only half of the patients always took their 
amino acid mixture. In contrast, good adherence to the protein restriction was reported in 98% but 80% said it was 
hard, time-consuming and caused unhappiness.
Conclusions: There is often a long delay in diagnosing the homocystinurias unless this is achieved by newborn 
screening; this survey also highlights problems with the availability and cost of treatment and the palatability of pro-
tein substitutes.
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Background
The homocystinurias are rare genetic disorders affect-
ing the metabolism of the non-proteinogenic amino acid, 
homocysteine. They are inherited as autosomal recessive 
traits. Homocysteine is formed during the catabolism of 
the amino acid, methionine. It can either be converted 
back to methionine by the remethylation pathway or 
converted to cystathionine and then to the amino acid, 
cysteine. Classical homocystinuria is caused by cystathio-
nine beta-synthase (CBS) deficiency [1]. The worldwide 
incidence of CBS deficiency is about 1:100,000–1:200,000 
[2], ranging from 1:1800 to 1:900,000 depending on eth-
nicity and method of case ascertainment.
The remethylation pathway depends on the coen-
zymes, methylcobalamin and methyltetrahydrofolate and 
Open Access
*Correspondence:  martina.huemer@kispi.uzh.ch
†M. Huemer and A. A. M.  Morris have contributed equally to this work
2 Division of Metabolism and Children’s Research Center, University 
Children’s Hospital Zurich, Zurich, Switzerland
Full list of author information is available at the end of the article
Page 2 of 12Morrison et al. Orphanet J Rare Dis          (2021) 16:124 
the main remethylation disorders are defects of methyl-
tetrahydrofolate recycling (methylenetetrahydrofolate 
reductase (MTHFR) deficiency) or cobalamin metabo-
lism. The latter may only affect methylcobalamin or also 
affect adenosylcobalamin synthesis. All remethylation 
defects are very rare diseases. Population frequencies 
cannot even be estimated for cblC disease, the common-
est remethylation defect, with several hundreds of pub-
lished cases worldwide.
For each of these disorders, there is a range of severity 
and age of presentation. Severe remethylation disorders 
(RMD) present in infancy, primarily with neurologi-
cal problems, such as acute encephalopathy (± seizures, 
apnoea or hydrocephalus) or severe developmental 
impairment [1, 3, 4]. Defects of cobalamin metabolism 
may also cause systemic problems, such as pancytope-
nia or haemolytic uraemic syndrome; patients may sub-
sequently develop visual impairment due to retinopathy. 
Milder RMD may cause learning difficulties or present 
with ataxia, psychiatric problems or thromboembolism. 
The cobalamin-related RMD are all treated with large 
doses of hydroxocobalamin, which need to be given by 
intramuscular or subcutaneous injection. Patients with 
cobalamin defects are also treated with the drug, betaine, 
which converts homocysteine to methionine using an 
alternative pathway. Treatment improves survival and 
morbidity but cognitive and visual impairment persist in 
many severe, early onset cases. Betaine prevents neuro-
cognitive deterioration if given early and is the drug of 
choice in patients with MTHFR deficiency, who should 
also be given mefolinate (methyltetrahydrofolate) as this 
is the only form of folic acid that crosses the blood brain 
barrier and it requires MTHFR for its synthesis [5].
Severe CBS deficiency presents in childhood with 
learning difficulties, dislocation of the optic lens, skeletal 
abnormalities and a predisposition to thromboembo-
lism, whereas partial CBS deficiency typically presents 
in adults with thromboembolism [6, 7]. CBS deficiency is 
treatable: pyridoxal 5´-phosphate is a coenzyme for CBS 
and patients with milder forms of CBS deficiency usually 
respond to treatment (in terms of lowering tHcy to target 
levels or even close to the normal range) with pharma-
cological doses of its precursor pyridoxine. In contrast, 
patients with severe deficiency require treatment with 
a diet very low in natural protein and supplements of a 
methionine-free cystine-enriched amino acid mixture. 
The drug, betaine, can also help to lower homocysteine 
concentrations. All complications can be prevented with 
pyridoxine (in responsive patients) or dietary treatment, 
if it is started early and there is good compliance [6]. Cur-
rently, newborn screening programmes targeting at least 
one of the homocystinurias (most frequently CBS defi-
ciency) are in place in several European countries such as 
the Czech Republic, Germany, Spain, the UK and Ireland; 




HCU Network Australia is a support group established 
by TM in 2014. Initially, it aimed to support the Austral-
ian families with CBS deficiency but it has acquired inter-
national members with CBS deficiency and RMD as there 
are few other support groups specifically for these dis-
orders. HCU Network Australia is not a member based 
organisation and as such the best way to describe its 
reach is based on its email/registry database. At the time 
of the survey there were 355 ‘members’/email contacts.
In 2018, an online survey was designed by TM using 
Survey Monkey software concerning the experiences of 
the homocystinuria community, primarily with respect 
to diagnosis and their satisfaction with current treat-
ment. The design took account of previous publications 
on patient surveys [9–11]. The survey was reviewed and 
edited by VK and the president of HCU Network Amer-
ica, Margie McGlynn. The survey was trialled for clarity 
of questions by 2 Australian caregivers and 1 American 
adult patient.
A total of 59 questions were asked (see Additional 
file 1). These included:
• General demographic information (sex, age at diag-
nosis, ethnicity)
• Was detection by newborn screening?
• Tests done (e.g. tHcy level at diagnosis and most 
recent)
• Symptoms and age of onset for each
• Diagnostic delay and perceived reasons
• Patient satisfaction with diagnostic process
• Treatment (type, frequency and mode of delivery)
• Patient satisfaction with treatment regime (e.g. low 
protein diet, amino acid mixture, medication)
• Satisfaction with medical care
There were opportunities for free comments (including 
about diagnosis and current treatment).
The 355 existing email contacts registered with HCU 
Network Australia at the time were contacted and invited 
to complete the survey online. The survey was placed 
on the HCU Network Australia website (www.HCUNe 
twork Austr alia.org.au) and visitors to the website were 
prompted to complete the survey. Information about 
the survey was also presented on the European Registry 
for Homocystinurias and Methylation Defects (E-HOD) 
project website (www.e-hod.org) and circulated on the 
social media channels of HCU Network Australia, of the 
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partnering patient organisation based in the US, HCU 
Network America, and of Cambrooke, an international 
medical foods company. In the Czech Republic the survey 
questions were translated into Czech with help from the 
patient organization NSPKU (Národní sdružení PKU a 
jiných DMP, z.s.) and patients and/or carers were invited 
to fill in appropriate fields in the on-line survey in Eng-
lish or Czech. The invitation to participate was distrib-
uted via announcement by NSPKU as well as by mailing 
to 37 patients followed in the General University Hospi-
tal. Anonymous entries in Czech were translated back to 
English by VK and deposited into the survey database. 
The survey was open from May 2018 to April 2019.
The study was initiated and carried out by patient 
organization HCU Network Australia, data were anony-
mous and no ethics committee approval was sought. The 
“Kantonale Ethikkommission Zürich” raised no concern 
regarding statistical analysis of the anonymised survey 
data.
Data cleaning
Double entries were detected from the IP addresses of 
the participants. In each case the most complete version 
was included. Two patients with methionine adenosyl-
transferase I/III deficiency were excluded, as the clinical 
course is distinct from the homocystinurias. Extreme, 
biochemically implausible outliers (e.g. total Hcy values 
exceeding 1000 µmol/l, probably confused with methio-
nine) as well as illogical answers (e.g. newborn screening 
not performed but diagnosis made by newborn screen-
ing) were excluded and handled as missing data.
Statistical methods
Statistical analyses were carried out with the statistical 
software package SPSS, version 24 for Windows [12]. For 
all tests a predefined significance level of p < 0.05 was set. 
Chi-square tests were conducted to assess differences 
between diagnosis subgroups (CBS and RMD) regarding 
reported symptoms and current treatment regimen. Chi-
square tests were also used to compare the psychological 
burden associated with different treatments (low protein 
diet, intake of amino acid mixtures, medication). A Fish-
er’s exact test was used if the number in any group was 
less than 5. Dependent t-tests were conducted to exam-
ine differences between most recent tHcy concentrations 
and tHcy concentrations prior to treatment. Two-tailed 
Pearson correlations were conducted to examine the rela-
tionship between age and diagnosis delay. Multiple linear 
regression analyses were conducted to determine predic-
tors of respondents’ satisfaction with treatment and med-
ical care. The a priori defined predictors [6, 13, 14] were 
patient age, patient gender, mode (newborn screening or 
clinically ascertained) and type of diagnosis (CBS, RMD), 
self- vs. proxy reporting, and diagnostic delay.
Results
Between May 2018 and April 2019, the survey was com-
pleted by 143 participants. Patient characteristics are 
summarised in Table 1.
Establishing the diagnosis
Median age at diagnosis in clinically ascertained patients 
was 3 years with a wide range between < 1 and 60 years. 
Newborn screening for homocystinuria was reported 
to have been undertaken in 43 (30%) patients and led 
to the diagnosis in 29 (67%) of these patients (Table  1). 
The remaining 14 (33%) patients who had a newborn 
screening but were not detected had MTHFR deficiency 
(2), cblC disease (1), partially pyridoxine responsive (2), 
and pyridoxine non-responsive (9) CBS deficiency. The 
diagnoses may not actually have been missed, as it is 
unknown which screening tests were undertaken in these 
patients in the newborn period.
In addition to those detected by newborn screening, 
14 patients (10%) were diagnosed in the first year (4 non-
pyridoxine responsive CBS deficiency; 1 unsure regarding 
responsiveness; 3 cblC, 1 cblG, 1 cblE defect; 2 MTHFR 
deficiency; 2 could not name the diagnosis). Distribution 
of diagnostic delay did not differ significantly between 
CBS and RMD and between subgroups of CBS according 
to pyridoxine responsiveness.
Plasma total homocysteine concentrations (tHcy) were 
significantly higher before compared to during treatment 
(i.e. at the time of the survey) (Table 2).
Symptoms were reported for 66 clinically ascertained 
patients (46.2%) (Fig. 1). The most common symptoms in 
infancy and childhood were developmental delay, learn-
ing difficulties and behaviour problems, reaching a peak 
at 2–4 years of age. Other common symptoms in child-
hood were clumsiness (mostly at 1–4 years) and myopia/
lens dislocation (most often at 3–4  years, though there 
was more than 1 case per year till 8  years). Significant 
differences of symptom frequencies between clinically 
ascertained CBS and RMD patients were detected for 
lens dislocation (p = 0.001) and myopia (“near-sight-
edness”; p = 0.017), which occurred almost exclusively 
in CBS deficiency, and seizures (p = 0.011), which were 
more frequent in RMD patients.
Clinically ascertained pyridoxine nonresponsive CBS 
patients reported significantly more frequently devel-
opmental delay (p = 0.002) and anxiety (p = 0.039) while 
responsive CBS patients had more thromboses (“blood 
clots”; p = 0.007) and pulmonary embolism (p = 0.05).
For 71 patients, the ages of the onset of symptoms 
and of diagnosis were both reported. Patient age at first 
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Table 1 Patient characteristics
N Median (IQR); mean ± SD
Patient age at the time of the survey
 Age of all patients 138 18 years (6–38); 22.7 ± 18
  Number of paediatric patients (≤ 18 years) 69
  Age of patients identified by newborn screening 29 4 years (2–22); 11.5 ± 13.2
  Age of clinically ascertained patients 76 21 years (10–38); 24.8 ± 17.3
N %
Participants 143
 Male 60 42
 Female 81 56.6
 No information provided 2 1.4
Informants
 Caregivers 82 57.3
 Adult patients (> 18 years) 55 38.5
 Adolescent patients (< 18 years) 2 1.4
 Health professionals 3 2.1
 No information provided 1 0.7
Countries of origin 141
 USA 46 32.6
 Czech Republic 20 14.2
 United Kingdom 19 13.5
 Australia 17 12.1
 Ireland 8 5.7
 Germany 6 4.3
 Other European countries 9 6.5
 South America 4 2.8
 Asia 4 2.8
 Canada 4 2.8
 Africa 2 1.4
 New Zealand 2 1.4
Diagnosis 142
   Cystathionine beta-synthase (CBS) deficiency 110 77.5
  Pyridoxine nonresponsive 62
   Diagnosed by newborn screening 21
  Partially pyridoxine responsive 8
   Diagnosed by newborn screening 1
  Pyridoxine responsive 28
   Diagnosed by newborn screening –
  Unsure of responsiveness 12
   Diagnosed by newborn screening 2
 Remethylation defects (RMD) 24 16.9
  cblC 10
   Diagnosed by newborn screening 4
  MTHFR deficiency 7
   Diagnosed by newborn screening –
  cblE 3
   Diagnosed by newborn screening –
  cblG 3
   Diagnosed by newborn screening –
cblF 1-
Diagnosed by newborn screening –
 Unsure of diagnosis 8 5.6
  Diagnosed by newborn screening 1
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symptoms correlated significantly with diagnostic delay 
(r = 0.246, p < 0.05). In clinically ascertained patients the 
diagnosis was made within a year of the initial symptom 
in 50% of patients, but in 12.5% it took > 15  years. The 
delay in diagnosis was largely attributed to doctors’ igno-
rance of the disease or to organisational problems. Forty-
five of the patients not identified by newborn screening 
(including 3 patients diagnosed within the first year of 
life) were initially given an incorrect diagnosis, such 
as Marfan syndrome, dyspraxia, developmental delay, 
behavioural or psychiatric problems, or autoimmune 
disease. Metabolic specialists (n = 24), ophthalmolo-
gists (n = 18), paediatricians (n = 8), neurologists (n = 6) 
or geneticists (n = 5) were the physicians who most fre-
quently raised the possibility of a homocystinuria.
The perceived difficulty of diagnosis, the number of 
physicians seen prior to diagnosis for patients identified 
by newborn screening or ascertained clinically and the 
perceived reasons for diagnostic delay are depicted in 
Fig. 2.
Communication of diagnosis
The diagnosis was given in person to 66% of patients/
parents, by telephone to 23% and in a letter to 1%. Only 
26% of patients were offered psychological support. Of 
102 respondents, 62% percent were satisfied with the way 
the diagnosis was delivered, 18% were neither satisfied 
nor dissatisfied but 17% thought it was unsatisfactory. 
Twenty-four percent of respondents felt they had been 
given insufficient information about the disease. Almost 
all respondents (98%) said they were interested in being 
kept informed of current research and clinical trials in 
the disease. Most respondents (90%) were extremely, 
highly or somewhat interested in joining support groups 
but only 21% were given information about these at the 
time of diagnosis and only 50% had found a relevant 
group in their country.
Free comments by participants showed that dissatis-
faction with communication of the diagnosis was mainly 
related to the perception of insufficient information pro-
vided, inappropriate communication behaviour and lim-
ited support from medical staff: “I would have preferred 
to have a psychological support”; “they didn’t even ask if 
my husband wanted to be there”. Some comments related 
to negative feelings elicited by the diagnosis: “shock, 
guilt, regret, grief, despair, hopeless”. Positive comments 
mostly related to finally having achieved a diagnosis (now 
I know what I have/my child has), or appreciated medical 
staff showing “kindness”, “support”, “concern” and “empa-
thy” that made families “feel like a priority”.
Current support and medical care
Information about current medical care was reported by 
99 participants. Eighty-nine of these said they attended a 
specialist clinic; 82 saw a metabolic specialist, 21 a genet-
icist, 12 a haematologist, 10 a paediatrician, 9 a neurolo-
gist and 17 a general practitioner—obviously, some saw 
more than one doctor but 2 reported having no health 
professional who managed their homocystinuria.
Care was considered good or excellent by 67% of 
respondents, average or fair by 29% and only 4% consid-
ered it poor. Nevertheless, 20% of respondents reported 
some difficulty talking to medical staff at clinics and a 
Table 1 (continued)
Cbl, cobalamin; IQR, interquartile range; MTHFR, methylenetetrahydrofolate reductase; SD, standard deviation
Table 2 Plasma total homocysteine concentrations (tHcy) before and during treatment (i.e. at the time of the survey)
tHcy (µmol/l) before treatment 
median (range) [n]
tHcy (µmol/l) at survey median 
(range) [n]
Statistical significance of difference 
[pairwise comparisons n] t-values
All CBS-deficient patients 257 (50–640) [44] 50 (6–310) [61] P < 0.001 [37]
10.804
Pyridoxine nonresponsive 200 (50–640) [20] 52 (6–310) [34] P < 0.001 [15]
6.837
Partially pyridoxine responsive 300 (99–412) [7] 26 (13–120) [8] P = 0.001 [7]
5.976
Pyridoxine responsive 257 (110–600) [12] 59 (11–180) [14] P < 0.001 [10]
6.166
RMD patients 145 (56–482) [11] 42 (7–95) [14] P = 0.006 [11]
3.433
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similar number reported difficulty getting an answer to 
questions between clinics.
Treatment
One hundred and five people gave information 
about treatment. Ten patients (9%) with CBS defi-
ciency received parenteral vitamin B12, which is not 
recommended as a disease-specific treatment but may 
have been used to supplement nutritional deficiencies.
As expected, low protein diets (p = 0.001), methionine-
free amino acid supplements (p = 0.01), and betaine 
(p < 0.05) were all used by a significantly higher propor-
tion of pyridoxine nonresponsive than responsive CBS-
deficient patients (Fig. 3). One RMD patient was said to 
*Seizures: p = 0.011; near-sightedness: p = 0.017
**Lens dislocaon: p = 0.001
*Anxiety: p = 0.039; pulmonary embolism: p = 0.05


















































B6 responsive B6 paral responsive B6 non-responsive
a
b
Fig. 1 a Percentage of self-/proxy-reported symptoms in clinically ascertained patients with CBS deficiency (n = 52) and RMD (n = 14). b 
Percentage of self-/proxy-reported symptoms in clinically ascertained pyridoxine responsive (n = 19), partially responsive (n = 7) and nonresponsive 
(n = 23) CBS patients
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Not at all difficult
Clinically ascertained % Newborn screening %





Clinically ascertained % Newborn screening  %
c
0 5 10 15 20 25 30 35
Lack of knowledge about the disease
amongst General Practitioners
Lack of knowledge about the disease
amongst specialists
Lack of symptom awareness by family
Delays in obtaining test results
Lack of access to appropriate tests
Long waiting times to see medical specialists
Responses clinically ascertained patients (%)
Fig. 2 The perceived difficulty of diagnosis for patients identified by newborn screening (n = 18) or ascertained clinically (n = 75) (a), the number 
of physicians seen prior to diagnosis for patients identified by newborn screening (n = 13) or ascertained clinically (n = 77) (b) and the perceived 
reasons for diagnostic delay (multiple answers possible) in clinically ascertained patients (c)
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be on a low-protein diet, which is not recommended; 4 
were taking amino acid mixtures.
Treatment‑related problems and patient satisfaction
Nearly forty percent of participants were extremely 
(11.1%) or very (27.3%) satisfied with the treatment but 
13.1% of patients were very dissatisfied and almost fifty 
percent considered treatment only partly satisfactory 
(somewhat = 40.4%; a little = 8.1%). The psychological 
burden of low protein diet, intake of amino acid mixtures 
and medication is shown in detail in Table 3.
Most participants (n = 67) reported no problems with 
the availability or affordability of drugs and vitamins but 
37 reported problems related to availability (“struggle to 
contact suppliers. Always out of stock”; “not available in 
my country”), financial burdens (“very expensive and the 
insurance does not cover”) or cumbersome administra-
tive and logistic processes (“My insurance doesn’t cover 
betaine and it takes months at a time to get it covered for 
a month’s supply. By the time I am covered my husband 
usually switches jobs (he does contract work) so we have 
a different insurance provider and then they deny cov-
erage of my medication and we have to go through the 
same long process over again to get the drug covered. It’s 
a vicious cycle”).
The financial burden on some patients was illustrated 
by the respondents’ estimate of the monthly additional 
costs of medications or vitamins to their family to a 
mean of 231 € (median 46; range 0 to 4495€). Additional 
monthly costs for specialised food accumulated to 154 € 
(median 75; range 0 to 1798 €).
Pairwise comparisons showed that carers reported 
significantly more arguments with their child about 
taking the amino acid mixture than about the pro-
tein restriction (p = 0.001). The need for amino acid 
mixtures also affected participation in activities more 
often than the protein restriction (p < 0.01). Patients 
who were on oral/parenteral medication and a low 
protein diet found it harder to take their medication 
(p < 0.01) than to adhere to the protein restriction.
Ninety-eight respondents said they/their child had 
adhered to the diet in the last seven days. Fifty percent 
of respondents (n = 23) reported always taking their 
amino acids but five (11%) reported missing it at least 
once per day.
Patient satisfaction with medical care
The regression model including patient age, gender, 
type of diagnosis (CBS, RMD), diagnostic mode (diag-
nosed by newborn screening/clinical ascertainment), 
source of report (self/proxy) and diagnostic delay as 
predictors and respondents’ satisfaction with treat-
ment and medical care as an outcome was signifi-
cant F(6,54) = 2.937, p = 0.016, adjusted R2 = 0.177). 
Patients’ age was a significant predictor (standardized 
β = 0.37, p = 0.039), older participants generally being 
more satisfied with their treatment and medical care. 
Additionally, diagnosis by newborn screening predicted 
significantly higher treatment satisfaction (standard-
ized β = 0.344, p = 0.013).
Discussion
Physicians, healthcare providers and companies produc-
ing medication, special food or amino acid mixtures all 
have much to learn from this survey, which is exceptional 
in being designed and undertaken by patient representa-
tives without the influence of medical professionals. It 
can, therefore, provide valuable insight into the prob-
lems faced by families with homocystinuria. Most of the 
Fig. 3 Treatment in CBS responsiveness subgroups and patients with RMD
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subjects had CBS deficiency with small numbers of RMD 
patients.
Patients and carers with these rare diseases clearly feel 
that diagnosis and treatment are significantly delayed 
by the ignorance of doctors and sometimes a shortage 
of diagnostic facilities and experts. Similar problems 
are experienced by patients with other rare diseases 
[15]. Clearly, one cannot expect general practitioners, 
physicians and paediatricians to be experts on all rare 
diseases. Unfortunately, the ‘diagnostic odyssey’ is par-
ticularly marked with the homocystinurias because most 
of the clinical features are non-specific, such as learn-
ing difficulties and clumsiness in children and thrombo-
embolism in adults. The patient or family’s frustration 
is compounded when the diagnosis is eventually made 
(following irreversible damage) and they learn that the 
condition is treatable. Metabolic specialists must teach 
mainstream specialist colleagues to have a low threshold 
for measuring plasma total homocysteine in patients with 
thromboembolism and children with learning difficulties. 
It should also be measured in all patients with dislocation 
of the optic lens, the most specific feature for CBS defi-
ciency: several patients in this survey were initially misdi-
agnosed as Marfan syndrome, as in previous series [16].
The diagnosis was made within a year of the first symp-
toms in half of the clinically ascertained patients in this 
survey but it was delayed by more than 15 years in 12.5% 
patients. The patient’s age at first presentation corre-
lated with the diagnostic delay. Long diagnostic delays 
have been found in previous series [16] and the delay has 
sometimes correlated with age [7, 13]. This reflects the 
particularly non-specific features in adult onset patients, 
who are generally pyridoxine-responsive. The data are 
compatible with those from the European Registry for 
Homocystinurias and Methylation Defects (E-HOD), 
which showed a median diagnostic delay of 1.6 years for 
pyridoxine-nonresponsive patients with CBS deficiency, 
increasing to 2.4 years in partial responders, 5.1 years in 
Table 3 Psychological burden of low protein diet, and intake of amino acid mixtures and medication
* 7 participants chose no category but explained verbally that there were arguments with the child about intake of the amino acid mixture
Never Yes A little of the 
time
Sometimes Most of the 
time
Always
In the past seven days did you/was it…
Argue with your child about intake of amino acid mixture? (n = 47)* 13 34 6 14 4 3
28% 72% 18% 41% 12% 9%
Hard to take amino acids? (n = 48) 13 35 14 13 4 4
27% 73% 11%
Hard to engage in activities due to intake of amino acid mixture? (n = 58) 28 30 12 12 4 2
48% 52% 40% 40% 13% 7%
Argue with your child about low protein diet? (n = 39) 17 22 11 11 – –
44% 56% 50% 50%
Hard to follow low protein diet? (n = 65) 12 53 18 22 10 3
19% 81% 34% 41% 19% 6%
Hard to engage in activities due to low protein diet? (n = 53) 23 30 16 9 – 5
43% 57% 53% 30% 17%
Did patient follow the low protein diet as directed? (n = 45) 1 44 2 9 – 33
2% 98% 4% 21% 75%
Feel unhappy about diet? (n = 61) 11 50 15 19 11 5
18% 82% 30% 38% 22% 10%
Enjoy eating when following diet? (n = 52) 1 51 8 9 – 34
2% 98% 16% 18% 66%
Want to eat what others eat? (n = 53) 11 42 8 17 – 17
21% 79% 19% 40.5% 40.5%
Preparing low-protein meals time consuming? (n = 48) 10 38 14 11 – 13
21% 79% 37% 29% 34%
Annoying/challenging to weigh or estimate protein content? (n = 49) 13 36 12 12 – 12
27% 73% 33.3% 33.3% 33.3%
Hard to take oral/parenteral medication? (n = 74) 43 31 11 13 – 7
58% 42% 35% 42% 23%
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full and 14  years in extreme responders requiring only 
low doses of pyridoxine [7]. The RMD in this series were 
diagnosed in early childhood, with a median delay of 
24 days, suggesting they were mostly severe, early-onset 
cases.
Newborn screening is well suited to treatable diseases 
whose clinical diagnosis is often delayed. Approximately 
one quarter of the patients in this survey had been 
detected by newborn screening and reported higher sat-
isfaction with the diagnostic procedure and with treat-
ment and medical care than those detected clinically. 
These numbers are relatively high since few countries 
undertake newborn screening for CBS deficiency and 
even fewer for RMDs; moreover, most of these have only 
introduced screening recently [8]. Reasons why coun-
tries do not screen for homocystinurias may include their 
rarity, high false positive rate if second tier tHcy is not 
measured and high false negative rate for pyridoxine-
responsive CBS deficiency and some RMD [8]. In this 
survey, 29 patients were ascertained by newborn screen-
ing while 14 patients who underwent newborn screen-
ing were not detected in the newborn period and were 
ascertained clinically; in the latter group of patients, it 
is unclear whether at the time of blood collection the 
respective screening programmes targeted the relevant 
form of homocystinurias.
The majority of patients thought that the diagnosis had 
been delivered in a satisfactory way but the survey shows 
there is still room for physicians to improve their com-
munication skills and to provide more information about 
the disease. Some respondents were unable to name 
their disease or to provide information about param-
eters critical for clinical decision making such as their 
plasma homocysteine values. Standardised, valid edu-
cation materials for patients with inborn metabolic dis-
eases have recently been developed [17] and are helpful 
for medical professionals and patients. Written informa-
tion about CBS deficiency and RMDs is available in most 
European languages on http://www.e-hod.org. Sadly, 
it comes as no surprise to find that few families were 
offered support from a psychologist following diagnosis 
as this resource has limited availability in many health-
care systems. Patients should, however, be informed 
about local metabolic support groups or international 
ones, such as HCU Network Australia, HCU Network 
America and cblC Onlus, Italy. In this survey, few were 
informed about support groups though most are keen to 
join and want to be kept informed of research and clini-
cal trials.
Additional problems for patients and carers include 
the cumbersome procedures for obtaining medica-
tions, amino acid supplements and other dietary prod-
ucts and—in some countries—the high cost of these. For 
patients on dietary treatment, taking the amino acid mix-
tures is reported to cause more problems than the dietary 
protein restriction. The amino acid mixtures available 
for CBS deficiency are less palatable than those for other 
disorders, such as phenylketonuria; this is related to the 
amino acid composition, such as the need for cystine, but 
it is clearly something for the medical food industry to 
work on. The diet does, however, cause significant stress: 
many patients do not enjoy eating and resent being una-
ble to eat like others; parents complain about frequent 
discussions about food with their affected children. It has 
recently been shown that patients with phenylketonuria 
and acute intoxication-type inborn errors of metabolism 
who should adhere to a protein-restricted diet have sig-
nificantly impaired health-related quality of life [18]. All 
of these factors contribute to the unmet need for psycho-
logical, financial and social support in patients and fami-
lies with homocystinuria.
The survey suggests that treatment of the homocyst-
inurias is not always in line with current recommen-
dations [3, 6]. One patient with a RMD was on protein 
restriction and 4 were said to receive amino acid mix-
tures. Protein restriction is not recommended in RMD. It 
was not specified whether amino acid intake was methio-
nine (which would be appropriate treatment) or a general 
amino acid mixture (which would not). Ten patients with 
CBS deficiency were on parenteral vitamin B12 treat-
ment, though this should only be necessary in RMD. It 
is possible that some patients with CBS deficiency had 
been vitamin B12 deficient and struggled with oral sup-
plements. Alternatively, it may be that some patients 
were receiving the (painful) injections unnecessarily. 
Approximately two thirds of the pyridoxine-nonrespon-
sive CBS deficient patients also took oral vitamins. Rou-
tine folic acid supplementation has been recommended 
for CBS deficiency as it is cheap and easy to take and it is 
important to avoid deficiency but oral pyridoxine is only 
indicated in responsive patients. Standardised testing of 
pyridoxine responsiveness in CBS deficiency has recently 
been recommended and would be helpful to tailor treat-
ment more precisely.
A low-methionine diet is recommended for pyridox-
ine-nonresponsive CBS deficient patients, achieved by 
severe protein restriction and methionine-free amino 
acid supplements. A quarter (27%) of these patients were 
on a normal diet. They may have been late diagnosed 
patients in whom diet is hard to introduce—resulting in 
sub-optimal treatment—or patients who have achieved 
homocysteine levels in the target range by taking betaine. 
Twenty patients with CBS deficiency were on a low-pro-
tein diet without an amino acid mixture. This may have 
been due to difficulty persuading some patients to take 
supplements whose taste is not particularly pleasant. 
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Sadly, in a number of cases the reason was probably una-
vailability of suitable amino acid mixtures, either because 
the patient cannot afford them or due to supply problems 
in their country. In these circumstances, treatment with a 
milder dietary protein restriction (minimum safe intake) 
and betaine may be the best that can be achieved. These 
patients require close monitoring of their nutritional sta-
tus and dietary intake.
While this study is unique with regard to providing 
information from patients and caregivers, several limita-
tions, mainly related to selection bias, need to be taken 
into account. The selection of topics the survey addresses 
was driven by individual experiences. Therefore, some 
aspects (e.g. the pathway to diagnosis) are covered in 
greater detail than others (biochemical values) and the 
results of this survey may not be completely representa-
tive. The majority of patients have a form of classical 
homocystinuria and very few individuals with RMD are 
included. The survey was distributed via patient support 
groups and the internet, which might have skewed par-
ticipation towards people involved in such groups and 
competent with internet-based surveys. The survey was 
in English with only a Czech translation available, which 
probably led to overrepresentation of English-speaking 
countries and people with above average education from 
other countries. There may also have been some inac-
curacy in the reporting of symptoms and biochemical 
values.
Conclusions
This survey was completed by an international group of 
carers and patients, most of whom had CBS deficiency 
with a smaller number of RMDs. Approximately one 
quarter of the patients had been detected by newborn 
screening. For many of the other patients, there was 
a long delay in diagnosis. Most of the patients are now 
under a metabolic specialist. Few were informed about 
support groups though most are keen to join these and 
receive more information about the disease. There is 
room for improvement of communication between medi-
cal professionals and patients/caregivers. Forty percent of 
participants were satisfied with the treatment but about 
20% of patients were very dissatisfied and 40% consid-
ered treatment only partly satisfactory. This may in part 
reflect the diagnoses. Treatment is easy and effective for 
pyridoxine-responsive CBS-deficient patients but dietary 
treatment is difficult for other CBS-deficient patients. 
Treatment is not very effective for patients with RMDs 
and patients with cobalamin defects may dislike their 
hydroxocobalamin injections.
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